Protective effect of GO-CoA-Tat on liver injury of mice with non-alcoholic fatty liver disease

Abstract

Abstract: Objective To investigate the protective effect of GO-CoA-Tat, an antagonist of Ghrelin o-acyltransferase, on liver injury of mice with non-alcoholic fatty liver.disease (NAFLD).Methods High fat diet (HFD) induced mice model of fatty liver disease was established. C57BL/6 male mice were feed with HFD for 8 weeks to induce chronic NAFLD. The mice were separately injected with physiological saline or GO-COA-TAT subcutaneously. The experimental groups included a Normal group, an HFD+Saline group and an HFD+GO-CoA-Tat group. Mice weights during feeding period were measured weekly. Microplate detection kits were used for detecting alanine aminotransferase (ALT), aspartame aminotransferase (AST), triglyceride (TG), total cholesterol (TC) and glucose (GLU). The cellular lipid assay kit was used for detecting the concentration of triglyceride in mouse liver. The changes in the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) mRNA expressions were detected by RT-PCR.Results GO-CoA-Tat significantly reduced the body weight gain of fatty liver mice, and the body weight of the HFD+GO-CoA-Tat group at week 8 (33.125±0.153) was significantly different from that of the HFD+Saline group (37.327±0.296) (P=0.014). There were significant differences in TG and TC (1.237±0.071, 2.403±0.151) in HFD+GO-CoA-Tat group and HFD+Saline group (1.943±0.136, 5.013±0.369) (P=0.038 and 0.029, respectively). The GLU of HFD+GO-CoA-Tat group (4.103±0.184) was significantly different than that of HFD+Saline group (6.370±0.296) (P=0.013). Compared with the HFD+Saline group (101.332±2.052), the liver triglyceride content of mice in HFD+GO-CoA-Tat group was significantly different (75.602±1.487) (P=0.027). There were significant differences in ALT and AST in the HFD+GO-CoA-Tat group (37.862±2.425, 122.932±6.907) and the HFD+Saline group (54.901±5.201, 173.321±13.971) (P=0.035 and 0.026, respectively). There were significant differences in TNF-α and IL-6 between the HFD+GO-CoA-Tat group (1.730±0.040, 1.630±0.040) and the HFD+Saline group (2.740±0.140, 2.980±0.070) (P=0.042 and 0.038, respectively).Conclusion GO-CoA-Tat has protective roles in NAFLD mice.

Key words: Nonalcoholic fatty liver disease, High fat diet, Ghrelin o-acyltransferase, Male mice, C57bl/6

ZHANG Shao-ren, HU Jing-xian, ZHOU Hao, JIANG Miao, FAN Xiao-ming. Protective effect of GO-CoA-Tat on liver injury of mice with non-alcoholic fatty liver disease[J]. Chinese Hepatolgy, 2022, 27(11): 1213-1215.

References

[1] Athyros VG, Polyzos SA, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Curr Vasc Pharmacol, 2020, 18: 172-181.
[2] Chávez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology, 2017, 152:1679-1694.
[3] 姚诚子, 冯巩, 宇文思, 等. 非酒精性脂肪性肝病发生及进展的危险因素.临床肝胆病杂志, 2020, 36: 433-436.
[4] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015, 149: 365-367.
[5] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, 64: 1388-1402.
[6] Isokawa M. Ghrelin-O-acyltransferase (GOAT) acylates ghrelin in the hippocampus. Vitam Horm, 2022, 118:369-392.
[7] Castorina S, Barresi V, Luca T, et al. Gastric ghrelin cells in obese patients are hyperactive. Int J Obes (Lond), 2021, 45:184-194.
[8] Song L, Yuan J, Liu Y, et al. Ghrelin system is involved in improvements in glucose metabolism mediated by hyperbaric oxygen treatment in a streptozotocin induced type 1 diabetes mouse model. Mol Med Rep, 2020, 22:3767-3776.
[9] Schalla MA, Stengel A. Pharmacological modulation of ghrelin to induce weight loss: successes and challenges. Curr Diab Rep, 2019, 19:102.
[10] Barnett BP, Hwang Y, Taylor MS, et al. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science, 2010, 330: 1689-1692.
[11] Iyer MR, Wood CM, Kunos G. Recent progress in the discovery of ghrelin O-acyltransferase (GOAT) inhibitors. RSC Med Chem, 2020, 11:1136-1144.
[12] Du GM, Luo BP, Hu ZH, et al. The effect of ghrelin O-acyltransferase inhibitor on gastric H+-K +-ATPase activity and GOAT/ghrelin system in gastric mucosal cells in vitro. Gen Comp Endocrinol, 2018, 267:167-171.
[13] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65: 1038-1048.
[14] Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J, 2020, 50:1038-1047.
[15] Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol, 2018, 69:927-947.
[16] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci, 2019, 19:994-1003.
[17] Zhang XY, Li S, Zhou YF, et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and brosis. Proc Natl Acad Sci USA, 2017, 114: 3181-3185.